文献速递肾移植慢性肾脏病

医学复杂活体肾捐献者的术前合并症与结局

Preoperative Comorbidities and Outcomes of Medically Complex Living Kidney Donors.
PubMed 文献 · Kidney Int Rep · 2019-10-10

本研究纳入802例活体肾捐献者,按术前合并症数量分为健康捐献者及1、2、3个合并症的医学复杂捐献者。结果显示合并症多的捐献者基线活检间质纤维化、肾小管萎缩、肾小球硬化及小动脉硬化更常见,但术后eGFR和短期死亡率无显著差异,未观察到明显蛋白尿或终末期肾病。

要点

  • 术前合并症多的活体肾捐献者基线肾脏病理异常更常见。
  • 术后eGFR和短期死亡率在健康与医学复杂捐献者间无显著差异。
  • 未观察到明显蛋白尿或终末期肾病发生。

核心结论

  • 对具有术前合并症的医学复杂活体肾捐献者进行适当的捐献后管理,可能获得与健康活体捐献者相似的结局。

研究设计与样本

  • 按术前合并症数量分为健康捐献者(无合并症,n=214)和医学复杂捐献者(1个合并症n=302、2个n=196、3个n=90)。

主要发现

  • 医学复杂捐献者(3个合并症)的间质纤维化、肾小管萎缩、肾小球硬化及小动脉硬化比健康捐献者更常见。
  • 健康捐献者与医学复杂捐献者术后eGFR和短期死亡率无显著差异。
  • 未观察到明显蛋白尿和终末期肾病。

临床怎么用

  • 对于有高血压、血脂异常、糖耐量异常或肥胖等合并症的活体肾捐献者,应进行个体化术前评估和捐献后管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent reports have described an increased risk of renal disease in living kidney donors compared with the general population. However, these reports do not detail the outcomes of medically complex living donors (MCLDs) with preoperative comorbidities (PCs), such as hypertension, dyslipidemia, glucose intolerance, and obesity. Analysis of living donors with end-stage renal disease (ESRD) has shown that these PCs may contribute significantly to the development of ESRD. We aimed to evaluate the effect of PCs on postoperative renal function and mortality in MCLDs. METHODS: Between January 2008 and December 2016, 807 living-donor kidney transplants were performed in our unit. Of these, 802 donors completed postoperative follow-up of >5 months. Donors were stratified into 4 groups based on the number of PCs present: healthy living donors (HLDs) with no PCs (n = 214) or MCLDs with 1 PC (n = 302), 2 PCs (n = 196), or 3 PCs (n = 90) (denoted MCLD [PC 1], MCLD [PC 2], or MCLD [PC 3], respectively). We compared pathology observation data from baseline biopsy, postoperative estimated glomerular filtration rate (eGFR), postoperative urinary protein concentration, and mortality between HLD and MCLD groups. RESULTS: Interstitial fibrosis, tubular atrophy, glomerulosclerosis, and arteriolosclerosis were more frequent in MCLDs (PC 3) than in HLDs. No significant differences were identified between HLDs and MCLDs in terms of postoperative eGFR and short-term mortality. Overt proteinuria and ESRD were not observed. CONCLUSIONS: Appropriate postdonation management of MCLDs with PCs may result in similar outcomes as for HLDs.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Hiramitsu T, Tomosugi T, Futamura K, et al. Preoperative Comorbidities and Outcomes of Medically Complex Living Kidney Donors. Kidney Int Rep. 2019. PMID: 31922057. doi:10.1016/j.ekir.2019.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。